Skip to main content

Feature article - CPHI Frankfurt: Strong markets, multiple modalities

Pharmaceutical CDMOs are continuing to invest in a buoyant market. We report from CPHI Frankfurt

The mood among CDMOs remained buoyant at the rebranded CPHI Frankfurt show, which took place on 1-3 November. There were several announcements of major investments and most of the exhibitors SCM spoke to were optimistic about continued rapid growth, particularly in new modalities of all kinds.

Feature article - The agchem CDMO opportunity: Maximising India’s share

Amit Gandhi and Amita Parekh, managing directors and partners at BCG, look at the opportunities for Indian CDMOS in the global agrochemical industry

If one were to imagine the ‘ideal’ industry for India’s chemical exports, it would most likely be globally relevant, with customers who outsource a significant percentage of the critical synthesis steps, and have a strong need for innovation and IP protection. agrochemical CDMO  industry ticks all these boxes.

CDMO expansion for AGC

AGC is to expand the production lines of its AGC Wakasa Chemicals subsidiary at the Kaminaka plant in Japan’s Fukui prefecture. The amount involved was not disclosed but the expansion, due to start operation in Q1 2024, will increase AGC Wakasa Chemicals’ manufacturing capacity by 50%, with more potentially to come.

More CDMOs in COVID-19 deals

The ongoing race to develop the first effective vaccines for the treatment of COVID-19 continues to generate manufacturing and development agreements between pharmaceutical giants, biotechs and CDMOs.

Most recently, Sterling Pharma Solutions agreed to carry out final purification of drug product for Moleculin Biotech’s WP1122 drug candidate from its site in Cary, North Carolina. Moleculin is about to submit an IND for this to the FDA and wanted a reliable source of supply in the US.

Subscribe to CDMOs